Despite advancements from first-generation (ibrutinib) to second-generation (acalabrutinib) BTK inhibitors, a consistent pattern emerges: the rate of complete responses plateaus around 36% over time. This suggests a potential biological limit for this class of drugs when used as monotherapy in CLL.
The linear progression through generations of BTK inhibitors may be a flawed strategy, as indefinite kinase blocking is unsustainable. The future likely lies in BTK degraders, a new drug class that eliminates the target protein entirely, offering a novel approach to overcoming resistance instead of just inhibiting the protein.
For elderly or comorbid patients, the high toxicity of powerful, time-limited combination therapies can outweigh their efficacy. A less harsh, continuous monotherapy is often preferable as it better preserves quality of life, even if it doesn't offer a treatment-free interval or a theoretical "100% life back."
The definition of the "best" BTK inhibitor is not purely clinical. When first-generation ibrutinib becomes generic and its price plummets, its affordability could make it the most practical and accessible option for many healthcare systems and patients, outweighing the better tolerance of newer, more expensive agents.
Early BTK inhibitors showed dramatic ~85% risk reduction against the old chlorambucil standard. However, when compared against the more effective bendamustine rituximab regimen, the hazard ratios, while still superior, are more modest (in the .20 to .30 range), contextualizing their true incremental benefit over contemporary options.